Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Merck
Teva
Boehringer Ingelheim
Cerilliant
Cantor Fitzgerald
Covington
AstraZeneca
Dow
Healthtrust

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,215,300

« Back to Dashboard

Which drugs does patent 8,215,300 protect, and when does it expire?


Patent 8,215,300 protects AFREZZA and is included in one NDA.

This patent has fifty-five patent family members in eighteen countries.

Summary for Patent: 8,215,300

Title:Unit dose cartridge and dry powder inhaler
Abstract: A dry powder inhaler having improved aerodynamic properties for diluting, dispersing, and metering drug particles for increasing the efficiency of pulmonary drug delivery to a patient is described. The inhaler comprises, in general, a housing having an air intake, an air flow-control/check-valve, a mixing section and a mouthpiece. A cartridge loaded with a single dose of medicament can be installed in the mixing section.
Inventor(s): Steiner; Solomon S. (Mount Kisco, NY), Poole; Trent A. (South Amherst, MA), Fog; Per B. (Bedford Hills, NY), Pohl; Roderike (Sherman, CT), Crick; Michael (Middlebury, CT), Feldstein; Robert (Yonkers, NY)
Assignee: MannKind Corporation (Valencia, CA)
Application Number:12/102,625
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
MannkindAFREZZAinsulin recombinant humanPOWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,215,300

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,061,111Unit dose capsules and dry powder inhaler► Subscribe
7,305,986Unit dose capsules for use in a dry powder inhaler► Subscribe
8,950,397Unit dose cartridge and dry powder inhaler► Subscribe
8,156,936Unit dose capsules and dry powder inhaler► Subscribe
8,671,937Unit dose capsules and dry powder inhaler► Subscribe
8,146,588Unit dose capsules and dry powder inhaler► Subscribe
7,464,706Unit dose cartridge and dry powder inhaler► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,215,300

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1200149► Subscribe
New Zealand577038► Subscribe
New Zealand545733► Subscribe
New Zealand516811► Subscribe
MexicoPA06002544► Subscribe
Mexico347170► Subscribe
MexicoPA02000812► Subscribe
South Korea20090074284► Subscribe
South Korea20080003462► Subscribe
South Korea100906269► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Julphar
Teva
Harvard Business School
Cipla
Chinese Patent Office
Argus Health
Deloitte
Merck
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot